Biolegend, 652403, PE anti-mouse Ki-67 Antibody, 25μg

The nuclear protein Ki-67 was first identified by the monoclonal antibody Ki-67, which was generated by immunizing mice with nuclei of the L428 Hodgkin lymphoma cell line. Ki-67 protein plays an essential role in ribosomal RNA transcription and cell proliferation. Expression of Ki-67 occurs during G1, S, G2, and M phase, while in G0 phase the Ki-67 protein is not detectable. Ki-67 is strongly expressed in proliferating cells and has been reported as a prognostic marker in various tumors.
25μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli expressed partial mouse Ki-67 recombinant protein, 1816-2163 aa.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by our Ki-67 staining protocol below. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application References(PubMed link indicates BioLegend citation): Medina-Reyes EI, et al. 2015. Environ Res. 136:424. PubMed Guillaumond F, et al. 2015. PNAS. 112:2473. PubMed Sharma SK, et al. 2015. J Immunol. 194:5529. PubMed Rodero MP, et al. 2014. J. Invest. Dermatol. 7:1991-7. PubMed
Product Citations: Wang YC, et al. 2023. J Exp Med. 220:. PubMed Lucas B, et al. 2023. Nat Commun. 14:2066. PubMed Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed Chan S, et al. 2022. Nat Cancer. . PubMed Cautivo KM, et al. 2022. Immunity. 55:254. PubMed Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed Li Y, et al. 2022. Brain Behav Immun. 101:1. PubMed Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed Liang J, et al. 2016. Nat Med. 22:1285-1293. PubMed Sizova O, et al. 2018. Mol Cancer Res. 16:1652. PubMed Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed Liu J, et al. 2015. Sci Rep. 5: 17569. PubMed Wu M, et al. 2021. Nat Commun. 12:3500. PubMed Ferretti M, et al. 2016. Brain Behav Immun. 54: 211-225. PubMed Mathur S, et al. 2021. JCI Insight. 6:. PubMed Yang F, et al. 2020. Cancer Res. 80:3677. PubMed Sharma S, et al. 2015. J Immunol. 194:5529. PubMed Sekiya T et al. 2018. Cell reports. 24(6):1627-1638 . PubMed Feng Y, et al. 2018. Kidney Dis (Basel). 4:95. PubMed Miyazaki M et al. 2017. Immunity. 46(5):818-834 . PubMed Saint Fleur–Lominy S, et al. 2018. Cell Rep. 24:3045. PubMed Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed Schneider MK, et al. 2018. Physiol Rep. 6:e13645. PubMed Giannini S, et al. 2020. Nat Commun. 0.705555556. PubMed Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed Song J, et al. 2021. Cancer Commun (Lond). 41:867. PubMed Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed Lee J, et al. 2020. Cell Reports. 33(13):108560. PubMed Godavarthy PS, et al. 2019. Haematologica. 104(10). PubMed Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed Shani O, et al. 2021. Elife. 10: . PubMed Watson MJ, et al. 2021. Nature. 591:645. PubMed Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed Lehrke MJ, et al. 2021. Elife. 10:. PubMed King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed Chen Z, et al. 2020. Cell Death Dis. 11:180. PubMed Sun X, et al. 2021. Nature. 599:673. PubMed Zhao X, et al. 2022. iScience. 25:104690. PubMed Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed Muzumdar S, et al. 2019. Am J Pathol. 189:568. PubMed Kim GC, et al. 2020. Front Oncol. 10:642. PubMed Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed Ghura H, et al. 2021. Neoplasia. 23:837. PubMed Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed Zamarin D, et al. 2020. Clin Cancer Res. 26:4531. PubMed Lawson M, et al. 2015. Nat Commun. 6: 8983. PubMed Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed Zhang Y, et al. 2021. JCI Insight. 6:e150735. PubMed Wang X, et al. 2022. Elife. 11:. PubMed Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed Nagatake T, et al. 2019. Mucosal Immunol. 12:p1082. PubMed Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed Oladiran O, et al. 2021. Front Immunol. 12:720733. PubMed Karimzadeh A, et al. 2021. Front Cell Dev Biol. 9:734176. PubMed Nguyen HD, et al. 2020. Cell Rep. 33:108316. PubMed
RRID: AB_2561524 (BioLegend Cat. No. 652403) AB_2561525 (BioLegend Cat. No. 652404)
Structure: 325 kD protein containing a forkhead-associated domain (FHA) and 13 tandem repeats
Distribution: Nucleus and chromosome
Function: Required for cell cycle progression and proliferation
Interaction: Interacts with KIF15; binds to MKI67IP through FHA domain
Biology Area: Cell Biology, Cell Cycle/DNA Replication, Transcription Factors
Molecular Family: Nuclear Markers
Antigen References: 1. Starborg M, et al. 1996. J. Cell. Sci. 109:143. 2. Byeon IJ, et al. 2005. Nat. Struct. Mol. Biol. 12:987. 3. Yerushalmi R, et al. 2010. Lancet. Oncol. 11:174. 4. Beltrami AP, et al. 2001. N. Engl. J. Med. 344:1750. 5. Sachsenberg N, et al. 1998. J. Exp. Med. 187:1295. 6. Nagy Z, et al. 1997. Acta. Neuropathol. 93:294.
Gene ID: 17345
UniProt: View information about Ki-67 on UniProt.org
Clone: 16A8
Regulatory Status: RUO
Other Names: KIA, proliferation-related Ki-67 antigen
Isotype: Rat IgG2a, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.